Tatsuo Kawai, Winfred W Williams, Nahel Elias, Jay A Fishman, Kerry Crisalli, Alban Longchamp, Ivy A Rosales, Michael Duggan, Shoko Kimura, Leela Morena, Thiago J Borges, Toshihide Tomosugi, Ahmad Karadagi, Tsukasa Nakamura, Kassem Safa, Alessia Giarraputo, Claire T Avillach, Eva D Patalas, R Neal Smith, David H Sachs, A Benedict Cosimi, Joren C Madsen, David K C Cooper, Richard Pierson, Steve Perrin, Ranjith P Anand, Sagar Chhangawala, Matthew Coscarella, Alexandre Daigneault, Feng Li, Owen Pearce, Wenning Qin, William T Serkin, Vincent Yeung, Kristen Getchell, Susan C Low, Michael Curtis, Robert B Colvin, Leonardo V Riella
{"title":"Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease.","authors":"Tatsuo Kawai, Winfred W Williams, Nahel Elias, Jay A Fishman, Kerry Crisalli, Alban Longchamp, Ivy A Rosales, Michael Duggan, Shoko Kimura, Leela Morena, Thiago J Borges, Toshihide Tomosugi, Ahmad Karadagi, Tsukasa Nakamura, Kassem Safa, Alessia Giarraputo, Claire T Avillach, Eva D Patalas, R Neal Smith, David H Sachs, A Benedict Cosimi, Joren C Madsen, David K C Cooper, Richard Pierson, Steve Perrin, Ranjith P Anand, Sagar Chhangawala, Matthew Coscarella, Alexandre Daigneault, Feng Li, Owen Pearce, Wenning Qin, William T Serkin, Vincent Yeung, Kristen Getchell, Susan C Low, Michael Curtis, Robert B Colvin, Leonardo V Riella","doi":"10.1056/NEJMoa2412747","DOIUrl":null,"url":null,"abstract":"<p><p>Xenotransplantation offers a potential solution to the organ shortage crisis. A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis-access challenges received a gene-edited porcine kidney with 69 genomic edits, including deletion of three glycan antigens, inactivation of porcine endogenous retroviruses, and insertion of seven human transgenes. The xenograft functioned immediately. The patient's creatinine levels decreased promptly and progressively, and dialysis was no longer needed. After a T-cell-mediated rejection episode on day 8, intensified immunosuppression reversed rejection. Despite sustained kidney function, the patient died from unexpected, sudden cardiac causes on day 52; autopsy revealed severe coronary artery disease and ventricular scarring without evident xenograft rejection. (Funded by Massachusetts General Hospital and eGenesis.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1933-1940"},"PeriodicalIF":96.2000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/NEJMoa2412747","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Xenotransplantation offers a potential solution to the organ shortage crisis. A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis-access challenges received a gene-edited porcine kidney with 69 genomic edits, including deletion of three glycan antigens, inactivation of porcine endogenous retroviruses, and insertion of seven human transgenes. The xenograft functioned immediately. The patient's creatinine levels decreased promptly and progressively, and dialysis was no longer needed. After a T-cell-mediated rejection episode on day 8, intensified immunosuppression reversed rejection. Despite sustained kidney function, the patient died from unexpected, sudden cardiac causes on day 52; autopsy revealed severe coronary artery disease and ventricular scarring without evident xenograft rejection. (Funded by Massachusetts General Hospital and eGenesis.).
期刊介绍：
The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
